Datapoint: Cigna to Eliminate Cost-Sharing From Two Gene Therapies

Sep 10, 2019

Cigna Corp. last week said it will make two gene therapies, Spark Therapeutics and Novartis’ Luxturna, which treat blindness, and Novatis’ muscular atrophy drug Zolgensma available to members at no cost. Gene therapies are among the most expensive drugs in the world, with Zolgensma currently holding the top spot. Cigna, which merged with Express Scripts in 2018, currently serves 16,400,235 people, with 82.9% enrolled in self-funded plans. Cigna said it would consider adding more gene therapies to the program as more become available.